Paper
Combination treatment of acute myeloid leukemia cells with DNMT and HDAC inhibitors: predominant synergistic gene downregulation associated with gene body demethylation
Published Oct 12, 2018 · Nadja Blagitko-Dorfs, P. Schlosser, G. Greve
Leukemia
Q1 SJR score
70
Citations
0
Influential Citations
Abstract
Abstract hidden due to publisher request; this does not indicate any issues with the research. Click the full text link above to read the abstract and view the original source.
In Vitro Study
Highly CitedStudy Snapshot
Combining DNMT and HDAC inhibitors in acute myeloid leukemia cells leads to synergistic gene downregulation, predominantly associated with gene body demethylation and changes in acH3K9/27.
PopulationOlder adults (50-71 years)
Sample size24
MethodsObservational
OutcomesBody Mass Index projections
ResultsSocial networks mitigate obesity in older groups.
Sign up to use Study Snapshot
Consensus is limited without an account. Create an account or sign in to get more searches and use the Study Snapshot.
Full text analysis coming soon...
References
DNMT and HDAC inhibitors induce cryptic transcription start sites encoded in long terminal repeats
DNMT and HDAC inhibitors induce cryptic transcription start sites encoded in long terminal repeats, leading to potentially abnormal or immunogenic proteins.
2017·237citations·D. Brocks et al.·Nature Genetics
Nature Genetics
Abstract B32: Inhibiting DNA methylation causes an interferon response in cancer via dsRNA including endogenous retroviruses
Inhibiting DNA methylation in cancer cells triggers an interferon response, potentially sensitizing patients to immunotherapy, through the activation of viral defense signaling.
2016·775citations·Katherine B. Chiappinelli et al.·Cancer Research
Cancer Research
Non-canonical PRC1.1 Targets Active Genes Independent of H3K27me3 and Is Essential for Leukemogenesis.
The non-canonical PRC1.1 complex plays a crucial role in leukemogenesis by targeting specific genes involved in unique cell biological processes, independent of H3K27me3.
2016·139citations·V. van den Boom et al.·Cell reports
Cell reports
Induction of cancer testis antigen expression in circulating acute myeloid leukemia blasts following hypomethylating agent monotherapy
Induction of cancer testis antigens (CTAs) in acute myeloid leukemia blasts after decitabine treatment allows for potential vaccination against NY-ESO-1, even in patients not responsive to HMA therapy.
2015·66citations·Pragya Srivastava et al.·Oncotarget
Oncotarget
The pan-HDAC inhibitor panobinostat acts as a sensitizer for erlotinib activity in EGFR-mutated and -wildtype non-small cell lung cancer cells
Panobinostat sensitizes lung adenocarcinoma cells to the antiproliferative effects of erlotinib, with the drug combination also having a robust effect on histone H3 acetylation and H3K4 methylation.
2015·62citations·G. Greve et al.·BMC Cancer
BMC Cancer
DNA-Demethylating Agents Target Colorectal Cancer Cells by Inducing Viral Mimicry by Endogenous Transcripts
Low-dose DNA-demethylating agent 5-AZA-CdR targets colorectal cancer-initiating cells by inducing viral mimicry, highlighting the MDA5/MAVS/IRF7 pathway as a potential druggable target.
2015·1125citations·David Roulois et al.·Cell
Cell
Abstract 5371: PRMT5 inhibitors as novel treatment for cancers
CTx-034 is a potent, highly selective inhibitor of PRMT5 methyltransferase activity, potentially offering a promising treatment for cancers by reducing pro-tumourigenic effects and promoting tumor cell death.
2015·3citations·Hendrik Falk et al.·Cancer Research
Cancer Research
International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts.
Azacitidine may be an important treatment option for older patients with newly diagnosed acute myeloid leukemia with >30% bone marrow blasts, offering increased median overall survival compared to conventional care regimens.
2015·1035citations·H. Dombret et al.·Blood
Blood
Citations
DNA methylation and immune evasion in triple-negative breast cancer: challenges and therapeutic opportunities
Combining DNA methylation inhibitors with immune checkpoint inhibitors shows potential for improving survival in triple-negative breast cancer patients by reversing immune evasion.
2025·0citations·Wen-yu Cai et al.·Frontiers in Oncology
Frontiers in Oncology
Deciphering the Therapeutic Potential of Novel Pentyloxyamide-Based Class I, IIb HDAC Inhibitors against Therapy-Resistant Leukemia.
Novel pentyloxyamide-based HDAC inhibitors (4d and 4m) show superior antileukemic activity and synergistic activity when combined with chemotherapeutics, offering potential for treatment of therapy-resistant leukemia.
2024·0citations·Fabian Fischer et al.·Journal of medicinal chemistry
Journal of medicinal chemistry
HDAC-driven mechanisms in anticancer resistance: epigenetics and beyond
HDACs play a key role in epigenetic mechanisms that contribute to anticancer drug resistance, influencing gene expression and potentially determining resistance to chemotherapy or other cancer treatments.
2024·2citations·Martina Minisini et al.·Cancer Drug Resistance
Cancer Drug Resistance
Epigenetic-modifying agents: the potential game changers in the treatment of hematologic malignancies.
Epigenetic-modifying agents show potential as a new treatment approach for hematologic malignancies, with current knowledge and ongoing clinical trials focusing on epigenetic modifications.
2024·0citations·Tahereh Hojjatipour et al.·Critical reviews in oncology/hematology
Critical reviews in oncology/hematology
Preferential HDAC6 inhibitors derived from HPOB exhibit synergistic antileukemia activity in combination with decitabine.
Preferential HDAC6 inhibitors derived from HPOB show synergistic antileukemia activity when combined with decitabine in acute myeloid leukemia treatment.
2024·3citations·Maik Tretbar et al.·European journal of medicinal chemistry
European journal of medicinal chemistry